Current investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing encouraging results in addressing excess mass and related 2 disease. Animal data suggest a novel mechanism contributing https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/